Introduction of PSA screening will increase total healthcare costs for prostate cancer substantially, of which the actual screening costs will be a small part.
In the case of prostate cancer screening, two systematic reviews have concluded that screening should not be carried out.
In general, this recommendation has been accepted in the United Kingdom.
the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer.
Increased usage of Prosdex leads to more informed decision making, the key aim of the UK Prostate Cancer Risk Management Programme.
.
